Department of Pathology, Manavgat State Hospital, Antalya, Turkey.
Department of Pathology, Ankara Education and Research Hospital, Ankara, Turkey.
Indian J Pathol Microbiol. 2020 Oct-Dec;63(4):551-558. doi: 10.4103/IJPM.IJPM_637_18.
The aim of this study is to evaluate the relationships between the expression of mucins in invasive breast carcinomas and clinicopathologic parameters.
We examined 150 cases of invasive breast carcinoma, using the 2012 World Health Organization (WHO) classification of the tumors of the breast. We studied the expression of MUC1, MUC2, MUC5AC, and MUC6 by immunohistochemistry. We also evaluated normal breast tissue and ductal carcinoma in situ (DCIS) lesions in nearby invasive tumor areas.
In invasive breast carcinomas, MUC1, MUC2, MUC5AC, and MUC6 were expressed in 98.6%, 11.3%, 9.9, and 8.5% of cases, respectively. MUC2, MUC5AC, and MUC6 were overexpressed in invasive tumors and DCIS lesions were compared with normal breast tissue. The apical pattern of MUC1 was correlated with low grade and ER expression. MUC2 was correlated with mucinous carcinoma and an inverse association with invasive ductal carcinoma, not otherwise specified (NOS). MUC6 expression was associated with lymphovascular invasion.
Most invasive breast tumors express MUC1 and the apical pattern of MUC1 is correlated with low grade and ER expression. MUC6 expression is associated with indicators of poor prognosis. Further comprehensive studies need to evaluate the role of mucins as a potential biomarker and to be used as a specific therapeutic target against breast cancer.
本研究旨在评估浸润性乳腺癌中黏蛋白的表达与临床病理参数之间的关系。
我们使用 2012 年世界卫生组织(WHO)乳腺肿瘤分类,对 150 例浸润性乳腺癌病例进行了研究。我们通过免疫组织化学方法研究了 MUC1、MUC2、MUC5AC 和 MUC6 的表达情况。我们还评估了临近浸润性肿瘤区域的正常乳腺组织和导管原位癌(DCIS)病变。
在浸润性乳腺癌中,MUC1、MUC2、MUC5AC 和 MUC6 的表达率分别为 98.6%、11.3%、9.9%和 8.5%。与正常乳腺组织相比,MUC2、MUC5AC 和 MUC6 在浸润性肿瘤和 DCIS 病变中过表达。MUC1 的顶泌型与低级别和 ER 表达相关。MUC2 与黏液癌相关,与非特殊型浸润性导管癌呈负相关。MUC6 的表达与脉管侵犯相关。
大多数浸润性乳腺癌表达 MUC1,且 MUC1 的顶泌型与低级别和 ER 表达相关。MUC6 的表达与预后不良的指标相关。需要进一步进行全面的研究,以评估黏蛋白作为潜在生物标志物的作用,并将其作为针对乳腺癌的特定治疗靶点。